Bicitropeptide, antacid and placebo in gastric and duodenal ulceration. A two-centre, double-blind, comparative endoscopic study.
S Afr Med J
; 55(2): 43-6, 1979 Jan 13.
Article
en En
| MEDLINE
| ID: mdl-371034
ABSTRACT
A bismuth-peptide complex (BCP Compound), an antacid (Maalox) and corresponding placebos were studied in a 6-week comparative double-blind trial of treatment in 106 randomized ambulant patients with endoscopically proven duodenal and gastric ulcers. Patients were examined after 1, 3 and 6 weeks' treatment and results assessed separately for duodenal and gastric ulcers on endoscopic evidence at weeks 3 and 6 respectively. Bicitropeptide was significantly better than antacid and placebo at 3 and 6 weeks for treatment of both duodenal and gastric ulcers. In the bicitropeptide group 100% of the patients in the duodenal ulcer group and 95,2% in the gastric ulcer group responded to treatment (improved or healed). No haematological or biochemical changes were noted and no adverse effects were recorded.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Bismuto
/
Proteínas
/
Úlcera Duodenal
/
Antiácidos
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
S Afr Med J
Año:
1979
Tipo del documento:
Article